FDA Approves Talazoparib Plus Enzalutamide for HRR-Mutated Metastatic Castration-Sensitive Prostate Cancer
Approved Oct. 26 for castration-sensitive disease, the PARP combination cut the risk of progression or death 52 percent. Survival data are immature.
On Oct. 26 the Food and Drug Administration approved talazoparib (Talzenna, Pfizer) with enzalutamide (Xtandi) for adults with metastatic castration-sensitive prostate cancer that carries a homologous recombination repair (HRR) gene mutation, moving the PARP inhibitor combination earlier than its previous castration-resistant indication.
The FDA's notice uses newer label language: metastatic "androgen pathway modulation-naive or -sensitive" disease, with the mutation detected by an FDA-authorized test. The agency had already approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics. The application received priority review and was handled under Project Orbis, with reviews by Australia's Therapeutic Goods Administration and Health Canada still under way.
What did TALAPRO-3 show?
TALAPRO-3 cut the risk of radiographic progression or death by about half. The randomized, double-blind, placebo-controlled phase 3 trial (NCT04821622) assigned 599 men with HRR-mutated disease 1:1 to enzalutamide plus talazoparib or placebo, all on continuous androgen deprivation therapy. The hazard ratio for investigator-assessed radiographic progression-free survival was 0.48 (95% CI, 0.36 to 0.65; P<.0001). Median rPFS was not reached with the combination and was 45.8 months with enzalutamide alone, OncLive reported from the trial data.
Eligibility allowed up to three months of prior androgen deprivation, with or without an androgen receptor pathway inhibitor, but no prior docetaxel in this setting. The HRR panel spanned 12 genes, including BRCA1, BRCA2, ATM, CDK12, CHEK2 and PALB2. The trial was presented as a late-breaking abstract at the 2026 American Society of Clinical Oncology meeting and published in the New England Journal of Medicine, CancerNetwork reported.
The effect was larger in BRCA-mutated disease (HR 0.368; 95% CI, 0.222 to 0.609) than in non-BRCA HRR alterations (HR 0.567; 95% CI, 0.392 to 0.819), according to CancerNetwork. Both confidence intervals exclude 1, but the non-BRCA estimate is the one to weigh for patients with ATM or CHEK2 alterations.
The progression benefit is clear. The survival benefit is not yet shown, and roughly half of treated patients had grade 3 or higher anemia.
Is there a survival benefit?
Not yet. The FDA says overall survival data were immature at the rPFS analysis. At the interim look, 36-month survival was 77.8 percent with the combination and 71.6 percent with enzalutamide alone, with 74 and 91 deaths, OncLive reported, and the trend did not reach significance (P=.0905), according to CancerNetwork.
How do benefit and harm compare?
By The Script Pad's arithmetic from the reported trial figures, the combination added 20.4 percentage points of 36-month rPFS (76.6 versus 56.2 percent), or roughly one additional patient free of radiographic progression at three years for every five treated. The same figures show 38 more percentage points of grade 3 or 4 adverse events (79 versus 41 percent) and 48 more points of grade 3 or higher anemia (51 versus 3 percent), roughly one additional case for every two treated. These are crude differences in Kaplan-Meier and event rates, not adjusted estimates.
Dose interruptions occurred in 69 percent of patients on talazoparib versus 31 percent on placebo, and dose reductions in 60 versus 7 percent. Talazoparib or placebo was permanently stopped in 19 versus 10 percent. Two treatment-related deaths occurred with talazoparib, from pancytopenia and worsening idiopathic pulmonary fibrosis. The label carries warnings for myelodysplastic syndrome and acute myeloid leukemia, myelosuppression and embryo-fetal toxicity. The labeled dose is talazoparib 0.5 mg once daily with enzalutamide, with a GnRH analog or prior bilateral orchiectomy; the trial used 0.35 mg in moderate renal impairment.
Neal Shore, M.D., medical director of the Carolina Urologic Research Center and a TALAPRO-3 investigator, told CancerNetwork the progression result was "remarkably impactful in terms of showing efficacy against progression for these patients."
What it means in clinic
The approval makes HRR testing at the castration-sensitive stage the gating step, as with other biomarker-restricted approvals this month. Practices should confirm that tissue or liquid testing is ordered at diagnosis of metastatic disease, not at progression, and plan for frequent blood counts in the first months; anemia was the dominant toxicity. For urology and oncology groups already adapting to new genitourinary indications, the practical question for each patient is whether a progression benefit, with survival still unproven, justifies the added marrow toxicity.
Reported, fact-checked and edited by The Script Pad's editorial staff. See How we use AI.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
